<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03732794</url>
  </required_header>
  <id_info>
    <org_study_id>CP2018-1</org_study_id>
    <nct_id>NCT03732794</nct_id>
  </id_info>
  <brief_title>AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment</brief_title>
  <acronym>ICE-AFIB</acronym>
  <official_title>AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment During Concomitant On-Pump Endo/Epicardial Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AtriCure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AtriCure, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and effectiveness of the
      AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with LAA
      exclusion using the AtriClip device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The AtriCure CryoICE Ablation System is being studied to ablate cardiac tissue during surgery
      for the treatment of Persistent and Long-standing Persistent atrial fibrillation in open
      concomitant cardiac surgery.

      The effectiveness of the device will be demonstrated by establishing that the device
      effectively eliminates persistent and long-standing persistent atrial fibrillation in a
      clinically significant proportion of treated patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2019</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Effectiveness Endpoint: Freedom from AF/AFL/AT</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from AF/AFL/AT lasting &gt;30 seconds in duration 12-months following the ablation procedure in the absence of Class I or III AADs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Endpoint: composite acute major adverse event (MAE) rate</measure>
    <time_frame>30 days</time_frame>
    <description>The composite acute major adverse event (MAE) rate, within 30-days post-procedure and deaths after 30-days if death is procedure related.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite post-procedure MAE rate (Safety).</measure>
    <time_frame>12 months</time_frame>
    <description>Long-term safety based on MAE rate at 12-months post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacemaker implantation (Safety).</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of implantation of a permanent pacemaker either in the operative period (&lt;30 days postoperative) or at any time during follow-up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall SAE rate (Safety)</measure>
    <time_frame>12 months</time_frame>
    <description>Long-term safety based on SAE rate at 12-months post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from AF/AFL/AT in presence of previously failed Class I or III AADs (Effectiveness)</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from AF/AFL/AT lasting &gt;30 seconds in duration 12-months following the ablation procedure in presence of previously failed Class I or III AADs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from AF/AFL/AT regardless of Class I or III AADs (Effectiveness)</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from AF/AFL/AT lasting &gt;30 seconds in duration 12-months following the ablation procedure regardless of Class I or III AADs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AFEQT QoL Score (Effectiveness)</measure>
    <time_frame>12 months</time_frame>
    <description>Based on composite score (0-100). A score of 0 corresponds to complete disability (or responding &quot;extremely&quot; limited, difficult or bothersome to all questions answered), while a score of 100 corresponds to no disability (or responding &quot;not at all&quot; limited, difficult or bothersome to all questions answered).
AFEQT Evaluates Health Related Quality of Life (HRQoL) across three domains Symptoms - Four questions specifically targeted to assess AF related symptoms Daily Activities - Eight questions that evaluate daily function in AF patients Treatment Concerns - Six questions that assess AF treatment concerns in patients The overall composite score and domains will be summarized by presenting the means, medians, standard deviations, interquartile ranges, minimum, and maximum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute procedural success (Effectiveness)</measure>
    <time_frame>Intra-operative period</time_frame>
    <description>Absence of AF at end of procedure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Persistent Atrial Fibrillation</condition>
  <condition>Longstanding Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>AtriCure CryoICE &amp; AtriClip LAA Exclusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AtriCure CryoICE system performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AtriCure CryoICE &amp; AtriClip LAA Exclusion</intervention_name>
    <description>AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.</description>
    <arm_group_label>AtriCure CryoICE &amp; AtriClip LAA Exclusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is greater than or equal to 18 years of age

          2. Subject has history of persistent or long-standing persistent atrial fibrillation as
             defined by the 2017 HRS/EHRA/ECAS Guidelines

          3. Stable Subject that is scheduled to undergo non-emergent cardiac surgical procedure(s)
             to be performed on cardiopulmonary bypass including open-heart surgery for one or more
             of the following: Mitral valve repair or replacement, Aortic valve repair or
             replacement, Tricuspid valve repair or replacement, and Coronary artery bypass
             procedures

          4. Left Ventricular Ejection Fraction â‰¥ 30% (determined by echocardiography or cardiac
             catheterization performed within 60 days of enrollment as documented in patient
             medical history)

          5. Subject is willing and able to provide written informed consent

          6. Subject has a life expectancy of at least 5 years

          7. Subject is willing and able to return for scheduled follow-up visits.

        Exclusion Criteria:

          1. Stand-alone AF without indication(s) for concomitant CABG and/or valve surgery

          2. Previous surgical Maze procedure

          3. Wolff-Parkinson-White syndrome or other Supra-Ventricular arrhythmia, AV nodal reentry

          4. Prior cardiac surgery (Redo)

          5. Subjects requiring surgery other than CABG and/or cardiac valve surgery and/or patent
             foramen ovale repair, and/or atrial septal defect repair.

          6. Class IV NYHA heart failure symptoms

          7. Prior history of cerebrovascular accident within 6 months or at any time if there is
             residual neurological deficit

          8. Documented ST elevation MI within the 6 weeks prior to study enrollment

          9. Need for emergent cardiac surgery (i.e. cardiogenic shock)

         10. Known carotid artery stenosis greater than 80%

         11. Documented AF duration of greater than five years

         12. LA diameter &gt;7 cm by TTE

         13. Current diagnosis of active systemic infection

         14. Severe peripheral arterial occlusive disease defined as claudication with minimal
             exertion

         15. Renal failure requiring dialysis or hepatic failure

         16. A known drug and/or alcohol addiction

         17. Mental impairment or other conditions which may not allow the subject to understand
             the nature, significance and scope of the study

         18. Pregnancy or desire to get pregnant within 12-months of the study treatment

         19. Preoperative need for an intra-aortic balloon pump or intravenous inotropes

         20. Requires anti-arrhythmic drug therapy for the treatment of a ventricular arrhythmia

         21. Subjects who have been treated with thoracic radiation

         22. Subjects in current chemotherapy

         23. Subjects on long term treatment with oral or injected steroids (not including
             intermittent use of inhaled steroids for respiratory diseases)

         24. Subjects with known connective tissue disorders

         25. Subjects with known hypertrophic obstructive cardiomyopathy

         26. Subjects with known cold agglutinin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niv Ad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington Adventist Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nfii K Ndikintum, PhD, MBA</last_name>
    <phone>513-644-8192</phone>
    <email>nndikintum@atricure.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Rhoades, CCRP, MSN</last_name>
    <phone>513-755-4561</phone>
    <email>mrhoades@atricure.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Mullin, RN</last_name>
      <phone>323-442-6226</phone>
    </contact>
    <investigator>
      <last_name>Vaughn Starnes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Satou, RN</last_name>
      <phone>310-206-4168</phone>
    </contact>
    <investigator>
      <last_name>Richard Shemin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington Adventist Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Yuan, RN,BSN,MHA</last_name>
      <phone>301-891-5612</phone>
    </contact>
    <investigator>
      <last_name>Niv Ad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Huskin, RN</last_name>
      <phone>312-695-4067</phone>
    </contact>
    <investigator>
      <last_name>Patrick McCarthy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Franciscan Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Cainfield, RN</last_name>
      <phone>317-893-1916</phone>
    </contact>
    <investigator>
      <last_name>Marc W Gerdisch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deaconess Gateway Hospital</name>
      <address>
        <city>Newburgh</city>
        <state>Indiana</state>
        <zip>47630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Johnson, RN</last_name>
      <phone>812-490-4505</phone>
    </contact>
    <investigator>
      <last_name>Dominic Cefali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Freshta Akbari</last_name>
      <phone>410-328-4562</phone>
    </contact>
    <investigator>
      <last_name>James Gammie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Shuler, RN</last_name>
      <phone>734-232-4297</phone>
    </contact>
    <investigator>
      <last_name>Matthew Romano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Icahn School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Fusilero</last_name>
      <phone>212-241-8905</phone>
    </contact>
    <investigator>
      <last_name>David Adams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYP-Weill Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Palaparthi</last_name>
      <phone>212-746-5594</phone>
    </contact>
    <investigator>
      <last_name>Leonard Girardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital Health Center</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Mowers, RN</last_name>
      <phone>315-234-4412</phone>
    </contact>
    <investigator>
      <last_name>Zhandong Zhou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ashville Heart/Mission Hospital</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie McPeters, RN</last_name>
      <phone>828-213-5679</phone>
    </contact>
    <investigator>
      <last_name>Mark Groh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Callihan</last_name>
      <phone>216-444-0379</phone>
    </contact>
    <investigator>
      <last_name>Marc Gillinov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Thomas West Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Crockarell, RN</last_name>
      <phone>615-222-6997</phone>
    </contact>
    <investigator>
      <last_name>Evelio Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chad Glaze</last_name>
      <phone>304-598-6092</phone>
    </contact>
    <investigator>
      <last_name>Vinay Badhwar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 5, 2018</study_first_submitted>
  <study_first_submitted_qc>November 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2018</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The study protocol, SAP, and ICF will be shared at the completion of the study.</ipd_description>
    <ipd_time_frame>Information will be available in accordance with clinical trials.gov requirements.</ipd_time_frame>
    <ipd_access_criteria>Publicly available through clinical trials.gov</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

